NCT05125016 2026-02-27
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT05570994 2026-01-08
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
British Columbia Cancer Agency
Phase 1/2 Enrolling by invitation
NCT06155084 2025-12-22
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Hinova Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05682443 2025-12-02
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT07172126 2025-09-15
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06383052 2025-05-21
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Norroy Bioscience Co., LTD
Phase 1/2 Active not recruiting
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT05340374 2025-04-06
LuCAB
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04060394 2024-10-10
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Laekna Limited
Phase 1/2 Completed
NCT05458544 2024-04-29
LUCIDA
FutureChem
Phase 1/2 Recruiting
NCT05405439 2023-11-03
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT03085966 2017-03-21
Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC
Shanghai AbelZeta Ltd.
Phase 1/2 Unknown